about
Expression of cyclin-dependent kinase inhibitor p15(INK4B) during normal and leukemic myeloid differentiationThe triggering receptor expressed on myeloid cells (TREM) in inflammatory bowel disease pathogenesisIntegrative systems medicine approaches to identify molecular targets in lymphoid malignanciesSurvival and cell cycle control in early hematopoiesis: role of bcl-2, and the cyclin dependent kinase inhibitors P27 and P21Cells with characteristics of cancer stem/progenitor cells express the CD133 antigen in human endometrial tumorsAdoptive immunotherapy with antigen-specific T cells during extracorporeal membrane oxygenation (ECMO) for adenovirus-related respiratory failure in a child given haploidentical stem cell transplantation.Interleukin-21 induces the differentiation of human umbilical cord blood CD34-lineage- cells into pseudomature lytic NK cells.Consistent bone marrow-derived cell mobilization following repeated short courses of granulocyte-colony-stimulating factor in patients with amyotrophic lateral sclerosis: results from a multicenter prospective trial.Indoleamine 2,3-dioxygenase 1 (IDO1) activity in leukemia blasts correlates with poor outcome in childhood acute myeloid leukemia.Effects of pegylated G-CSF on immune cell number and function in patients with gynecological malignanciesThymoglobulin, interferon-γ and interleukin-2 efficiently expand cytokine-induced killer (CIK) cells in clinical-grade cultures.Tolerogenic dendritic cells: cytokine modulation comes of age.MyoD expression restores defective myogenic differentiation of human mesoangioblasts from inclusion-body myositis muscle.Inhibitors of indoleamine 2,3-dioxygenase: a review of novel patented lead compounds.Cell cycle regulation in human hematopoietic stem cells: from isolation to activation.Cyclooxygenase-2 (COX-2) inhibition constrains indoleamine 2,3-dioxygenase 1 (IDO1) activity in acute myeloid leukaemia cells.Revving up Natural Killer Cells and Cytokine-Induced Killer Cells Against Hematological Malignancies.Circulating hematopoietic stem cells and putative intestinal stem cells in coeliac diseaseReduced cortical thickness in patients with acute-on-chronic liver failure due to non-alcoholic etiology.Granulocyte transfusions in children and adults with hematological malignancies: benefits and controversiesTreatment of acute leukaemias with monoclonal antibodies: current status and future prospects.Indoleamine 2,3-dioxygenase 1 (IDO1) activity correlates with immune system abnormalities in multiple myeloma.Granulocyte colony-stimulating factor for the induction of T-cell tolerance.Function and dysfunction of dendritic cells in autoimmune rheumatic diseases.Targeting indoleamine 2,3-dioxygenase (IDO) to counteract tumour-induced immune dysfunction: from biochemistry to clinical development.Enhanced platelet adhesion induces angiogenesis in intestinal inflammation and inflammatory bowel disease microvasculature.Systematic evaluation of immune regulation and modulationTargeting multiple-myeloma-induced immune dysfunction to improve immunotherapy outcomes.Emerging concepts on inhibitors of indoleamine 2,3-dioxygenase in rheumatic diseases.At the Bedside: Innate immunity as an immunotherapy tool for hematological malignancies.Extracorporeal photopheresis for paediatric patients experiencing graft-versus-host disease (GVHD).Recent advances on cellular therapies and immune modulators for graft-versus-host disease.The Polycomb group (PcG) protein EZH2 supports the survival of PAX3-FOXO1 alveolar rhabdomyosarcoma by repressing FBXO32 (Atrogin1/MAFbx).Adoptive immunotherapy with cytokine-induced killer cells generated with a new good manufacturing practice-grade protocol.Angiogenesis as a novel component of inflammatory bowel disease pathogenesis.Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25- into CD25+ T regulatory cells.Granulocyte colony-stimulating factor enhances the in vitro cytotoxicity of gemtuzumab ozogamicin against acute myeloid leukemia cell lines and primary blast cells.The novel lipophilic camptothecin analogue gimatecan is very active in vitro in human neuroblastoma: a comparative study with SN38 and topotecan.Anti-HIV effects of chloroquine: inhibition of viral particle glycosylation and synergism with protease inhibitors.Indoleamine 2,3-dioxygenase-expressing leukemic dendritic cells impair a leukemia-specific immune response by inducing potent T regulatory cells
P50
Q22254103-9D73F5CB-5945-40B1-B41A-D914E88B08CFQ26862713-5D1D88EF-C8AB-40A7-A309-83C42FB854F7Q28067817-0CD26745-D159-432A-9CA8-49AEB72E0787Q28209016-3EF57C08-765A-494E-A975-F18FF4D1CC19Q28247911-DD43EA01-BE5F-4810-B1A5-7C797927770CQ33410361-AA0B49C6-D361-4BD7-B5E5-0CEAE5A4A551Q33497623-0195F91B-893B-4261-B2A1-C655D16014DEQ33514075-877CB746-B220-4270-B265-0AF981620C51Q33688517-3E255DA2-0185-4B74-8708-8A12542FF7D6Q34353567-EFDAC110-71B9-4A2E-92F8-A037DB7887C1Q34419059-0B1C0315-3278-48B9-8FDF-15EDFFBC2FA8Q34523591-3A7E58FB-A758-445B-82D1-FDF3270C3E63Q34578181-81B198DF-3C12-4F25-8DF4-96158FA32DFBQ34616168-31301767-F270-4DA6-A16C-7FBCEFF5007DQ34632477-735D16EE-ACBB-41B9-969F-678A0CF5B470Q34655638-F57FC696-0F58-487C-8EAF-1FA8B082569EQ35600095-29EA7325-7D6B-4E9C-9C92-50A7BCEA7952Q35838460-765F1DB9-F5C0-4008-A14B-0A5E605C7B2EQ36131807-0BA50D3F-AAFC-4E31-AF82-49222DE6B54AQ36286585-B9F074F5-6F15-41A8-A5F0-EC45011F58CFQ36418067-89EAB4EE-7EA9-48DA-A05B-91EC2EE44CC1Q36526999-CFCDB938-0015-49D6-A415-0B21A9CF4410Q36882397-523B701F-18EA-4E93-AC1D-33B1DE751E43Q37465097-084FC791-35E1-4A74-9BC2-BFE36FAFCFA7Q37516009-26C3377C-2DCC-40D1-9A54-D748FB498ECDQ37580251-C4B02963-7F9B-4529-A1A0-3203B6DC1D2CQ37713498-C761ADC1-B036-440D-8FEA-F7AB1F34BFD1Q38008379-8261F576-E56C-49E0-BC4F-0CDBFFEDC254Q38042154-064AC263-6E6F-46FF-B5EF-20F10D858B4DQ38149725-842BC09C-3428-435D-9BCD-5F135580D3CAQ38208101-E37524D2-EEB6-48BC-A9BD-E1CE0EFD067AQ38246755-BD8DF3A1-3E7F-4D93-B1CD-3511A10E7A92Q39064876-79B6F9C0-AE58-4B44-9673-B4B79A59974FQ39620578-87C3A3DA-123C-46B1-BC08-AAB8D77F39C3Q39758196-463DB46C-0B37-423D-8D00-7697B1214C8DQ40197317-CC950694-582A-420D-85B7-98B30ECAA980Q40329688-FDAD948A-0099-4E72-86C6-653505EFE57FQ40378461-C130D6B7-A7FA-423B-8376-011242359E05Q40568140-55E0EE9E-928E-4E44-ADD9-F4BFBE16883EQ41326662-49AAC38E-7B27-42FA-B6B8-04DD7887E5F3
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Sergio Rutella
@ast
Sergio Rutella
@en
Sergio Rutella
@es
Sergio Rutella
@nl
Sergio Rutella
@sl
type
label
Sergio Rutella
@ast
Sergio Rutella
@en
Sergio Rutella
@es
Sergio Rutella
@nl
Sergio Rutella
@sl
prefLabel
Sergio Rutella
@ast
Sergio Rutella
@en
Sergio Rutella
@es
Sergio Rutella
@nl
Sergio Rutella
@sl
P106
P1153
7004418747
P21
P31
P496
0000-0003-1970-7375